^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    5d
    Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=0, Temporarily Not Available, Daiichi Sankyo
    New trial
    |
    ifinatamab deruxtecan (DS-7300)
    5d
    A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors (clinicaltrials.gov)
    P1/2, N=326, Not yet recruiting, RemeGen Co., Ltd.
    New P1/2 trial
    |
    misitatug blivedotin (RC88)
    5d
    YL201-INT-102-02: A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (2025-523742-27-00)
    P1/2, N=133, Not yet recruiting, Medilink Therapeutics (Suzhou) Co. Ltd. | N=51 --> 133
    Enrollment change
    |
    Tecentriq (atezolizumab) • YL201
    13d
    ARTEMIS-011: Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure (clinicaltrials.gov)
    P3, N=117, Active, not recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • docetaxel • risvutatug rezetecan (GSK5764227)
    13d
    A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=118, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tecentriq (atezolizumab) • YL201
    15d
    A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • ifinatamab deruxtecan (DS-7300)
    20d
    Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. (PubMed, Lancet Oncol)
    The maximum tolerated dose was not reached with ifinatamab deruxtecan; however, one death due to treatment-related interstitial lung disease highlights the importance of prompt evaluation and careful management of patients who develop interstitial lung disease. Promising antitumour activity was observed across various solid tumours. These findings support further evaluation of ifinatamab deruxtecan in randomised controlled trials.
    P1/2 data • Journal • Pan tumor • First-in-human
    |
    CD276 (CD276 Molecule)
    |
    ifinatamab deruxtecan (DS-7300)
    20d
    SKB500-II-02: SKB500 Combinations in Patients With Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • etoposide IV • Cotelet (tagitanlimab)
    20d
    IDeate-Prostate01: A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (clinicaltrials.gov)
    P3, N=1440, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    docetaxel • prednisone • ifinatamab deruxtecan (DS-7300)
    22d
    A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types (clinicaltrials.gov)
    P1, N=150, Recruiting, IDEAYA Biosciences
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule) • PTK7 (Protein Tyrosine Kinase 7)
    |
    HER-2 negative
    28d
    A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (clinicaltrials.gov)
    P1/2, N=360, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2030 --> Apr 2031 | Trial primary completion date: Feb 2030 --> Apr 2031
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • ifinatamab deruxtecan (DS-7300) • opevesostat (MK-5684)
    30d
    A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • YL201